Dominic G Rothwell, Mahmood Ayub, Natalie Cook, Fiona Thistlethwaite, Louise Carter, Emma Dean, Nigel Smith, Shaun Villa, Joanne Dransfield, Alexandra Clipson, Daniel White, Kamrun Nessa, Saba Ferdous, Matthew Howell, Avinash Gupta, Bedirhan Kilerci, Sumitra Mohan, Kris Frese, Sakshi Gulati, Crispin Miller, Allan Jordan, Helen Eaton, Nicholas Hickson, Ciara O'Brien, Donna Graham, Claire Kelly, Sreeja Aruketty, Robert Metcalf, Jaseela Chiramel, Nadina Tinsley, Alexander J Vickers, Roopa Kurup, Hannah Frost, Julie Stevenson, Siobhan Southam, Dónal Landers, Andrew Wallace, Richard Marais, Andrew M Hughes, Ged Brady, Caroline Dive, Matthew G Krebs
Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) supports blood-based genomic profiling but is not yet routinely implemented in the setting of a phase I trials clinic. TARGET is a molecular profiling program with the primary aim to match patients with a broad range of advanced cancers to early phase clinical trials on the basis of analysis of both somatic mutations and copy number alterations (CNA) across a 641 cancer-associated-gene panel in a single ctDNA assay. For the first 100 TARGET patients, ctDNA data showed good concordance with matched tumor and results were turned round within a clinically acceptable timeframe for Molecular Tumor Board (MTB) review...
May 2019: Nature Medicine